Regulatory decisions affecting biopharma products in development, including: Acacia, Alnylam, Amgen, Ascletis, Biocryst, Biohaven, Biomarin, BMS, Can-Fite, Cortexyme, Debiopharm, Eli Lilly, Enochian, Epizyme, Fibrogen, Forma, Genentech, Genmab, GSK, Heron, Horizon, Incyte, Innocoll, Inovio, Ionis, Janssen, Jazz, Kiadis, Kyowa Kirin, Logicbio, Lysogene, Merck, Mesoblast, Monopar, Nanobiotix, Neurosense, Novan, Novartis, Pharmamar, Phasebio, Protalix, Puma, Revance, Roche, Shionogi, Sirnaomics, Soligenix, Takeda, Trevena, Ultragenyx, United, Y-mabs, Zai Lab, Zogenix.

The importance of artificial intelligence and machine learning (AI/ML) has not been lost on drug development companies. Recently, to help accelerate the discovery of therapies to treat COVID-19, several deals have been established to help deploy those tools.

The circuit breakers activated almost immediately when the markets opened this morning as the Dow plummeted, with investors moving into cash and away from equities. Clearly, they were not impressed with the Federal Reserve’s decision to slash its benchmark interest rate to nearly 0% to help combat the economic fallout from the coronavirus outbreak.

Therapeutic area data reported by biopharma companies on phase I trials in February 2020, including: Abeona, Actinium, Advaxis, Agenus, Apeiron, Aravive, Arrowhead, Aura, BMS, Celltrion, Ciclomed, Compugen, Corvus, Cyclo, Cytodyn, Cytomx, Exelixis, Faron, Freeline, Genetx, Genprex, Harbour, Immix, Incysus, Inflazome, Innovation, Ionctura, Iteos, Kodiak Sciences, Matinas, Mirati, Moderna, Moleculin, Neurimmune, Noxopharm, Ocular, Oxurion, Pandion, Phasebio, Regulus, Reneo, Restorbio, Sernova, Soricimed, Sorrento, Takeda, Transgene, Urovant.